Nirsevimab for RSV Prevention in Late Preterm and Term Infants | NEJM

• 2022

  Log in to bookmark this resource.

  Log in

---

Access Resources

• Job AidEN
• Ask aRCie About This Resource

About

This short video summarizes new research findings on nirsevimab and how it can prevent RSV in late preterm and term infants. The trial included 1490 infants born at 35 weeks gestation or later. Results showed a lower incidence of RSV-associated infections in the nirsevimab group compared to the placebo group. Adverse events were similar between the two groups. Researchers concluded that nirsevimab effectively reduced the risk of RSV infections in healthy infants born at 35 weeks gestation or later.

---

Tags

Focus Area: Infectious Disease

Audiences: Nurses; Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Infant; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Respiratory Tract Infections; Premature Birth; Antibodies, Monoclonal, Humanized

Institutions: NEJM Group

---

More like this

Rapid Hospital Readiness Checklist: A Module from the Suite of Health Service Capacity Assessments in the Context of the COVID-19 Pandemic 2020 · World Health Organization (WHO) Advice on the Use of Masks for Children in the Community in the Context of COVID-19 2020 · United Nations Children's Fund (UNICEF), World Health Organization (WHO) Preparedness for Cyclones, Tropical Storms, Tornadoes, Floods and Earthquakes During the COVID-19 Pandemic 2020 · World Health Organization (WHO)

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---